Posts

Posted on

Despite COVID-19, Canadians Provide 7.8 Million Meals and More in the Caribbean and Latin America

TORONTO, Dec. 22, 2020 (GLOBE NEWSWIRE) — Food For The Poor Canada (FFPC) moved quickly in early 2020 to address the impact of COVID-19 in vulnerable Latin American and Caribbean communities. While Canadians experienced lockdowns and loneliness, they continued to be generous to families in other countries who were affected more severely. FFPC was able to ship a record 23 containers of food and medical supplies and moved forward on projects in underserved communities in Jamaica, Honduras, Haiti, Bahamas and Guyana.

7.8 million meals reached children in orphanages and schools, hospital patients, prisoners, the elderly, people with disabilities, and families who had lost all sources of income. Canadian farmers donated their surplus food to be processed into dry soup mix by FFPC partners, the Gleaners. Monies donated were used to purchase ten 40-foot containers of rice and beans.

Local clinics and hospitals in Haiti, Jamaica, Guyana and Honduras received medicine, masks, hand sanitizer and face shields to protect staff and patients. A staff member at a recipient clinic says, “At this time, when the entire world is being affected by COVID-19, the unselfish, caring and compassionate outreach to help others is remarkable.”

Delays and safety precautions have not stopped critical projects from moving forward. Ten homes were completed in Derac, Haiti just in time for Christmas. An Ontario high school built a home in Jamaica for a physically disabled senior; this was the last volunteer build before the pandemic. Also in Jamaica, Martin Primary & Infant School was rebuilt after a fire, thanks to FFPC’s donor Helping Hands Jamaica Foundation; a second early childhood school broke ground in Portland, and a resource center with computer room and library was completed in Portmore. In Baramita, Guyana, where many have limited access to nutrition, education and safe housing, the remote village has a new community centre thanks to a group of dedicated Canadian donors; programs to combat gender-based violence began taking place in the first few weeks of its completion.

“This Christmas week, as much of Canada is in lockdown to protect ourselves and our neighbours, we are so grateful that you are also helping protect and take care of others in the hardest of times. Your gifts make a real difference to families who will be able to better endure this pandemic thanks to you,” says FFPC’s Executive Director, Samantha Mahfood.

2021 will start with hope as FFPC and its donors build a new agricultural school in Honduras and continue to support families with food. To support those in need in the Caribbean and Latin America this Christmas, please visit: www.foodforthepoor.ca/make-a-donation

Food For The Poor Canada empowers communities in Latin America and the Caribbean through five areas of programming: food, housing, education, health and income-generating projects. FFPC responds to urgent needs while building community and social infrastructure. FFPC utilizes the pre-existing infrastructure of local affiliated organizations to better sustain and grow the communities they serve and responds effectively to emergencies and natural disasters when they occur. Over the last 12 years, FFPC and its Canadian donors have built 142 homes, 34 schools, as well as shipped and distributed $40,000,000 in food, educational and medical supplies to communities across the region.

For interviews or more information, contact:

Samantha Mahfood
Executive Director
(416) 921-4008
[email protected]
www.foodforthepoor.ca

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4adcfe3a-0c6f-44a3-bd97-b9e4601c853a

https://www.globenewswire.com/NewsRoom/AttachmentNg/e2f1fbb5-bd15-4378-b985-6cf6f92be8ee



Posted on

Middlesex Water VP Robert K. Fullagar Among Several Water Professionals Honored for Water Sector Response to COVID-19

ISELIN, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) — Middlesex Water Company (NASDAQ: MSEX), a provider of water, wastewater and related services, announced today that its Vice President – Operations, Robert K. Fullagar, P.E. is among four individuals recently honored by The NJ Water Association (NJWA), an organization which provides training, technical assistance and support to water and wastewater systems of all sizes throughout New Jersey. Fullagar, with over thirty years of water management experience, received recognition from NJWA, along with Mitzi Kaiura, NJDEP Emergency Management Program; John Rouse of the Brick Township MUA and Chris O’Shea of the Passaic Valley Sewerage Commission for their efforts in early 2020 relating to the water sector’s response to the COVID-19 pandemic and operational resiliency initiatives.

Awards were presented by NJWA President, Michael Barnes, and the NJWA Executive Director, Richard Howlett to the individuals in recognition of managerial and operational guidance provided as the COVID-19 pandemic emerged. Water and wastewater utilities prepared to provide uninterrupted services, regulatory compliance and implemented health and safety protocols to keep personnel — including treatment plant operators safe. Working around the clock, the honorees provided significant contributions in the development of the COVID-19 Best Management Practices guide which enabled the industry to understand, plan, adapt and overcome the challenges related to COVID-19. As a result of the joint effort, New Jersey’s water and wastewater sector is better equipped today to deal with this and other challenges facing the industry.

“I am honored to be recognized by NJWA,” said Fullagar, “and I extend my sincere appreciation to NJWA Executive Director Rick Howlett for the steady guidance and technical assistance provided to the Sector and Licensed Operators throughout the pandemic. COVID-19 posed interesting challenges for all of us in the water and wastewater industry, in terms of operational readiness, maintaining compliance and workforce safety. Sharing knowledge and collaborating with other industry professionals enabled each of our organizations to quickly develop and rapidly build upon existing Emergency Response Plans that continue to protect the health and safety of our staff and the public,” added Fullagar.

About Middlesex Water Company

Established in 1897, Middlesex Water Company (NASDAQ:MSEX) serves as a trusted provider offering life-sustaining high quality water service for residential, commercial, industrial and fire protection purposes. The Company offers a full range of water, wastewater utility and related services. An investor-owned public utility, Middlesex Water is a professional services provider specializing in municipal and industrial contract operations and water and wastewater system technical operations and maintenance. The company and its subsidiaries form the Middlesex Water family of companies, which collectively serve a population of nearly half a million people in New Jersey and Delaware.  Named a 2020 Top Workplace in New Jersey, Middlesex is focused on meeting the needs of its employees, customers, and shareholders. The Company invests in its people, infrastructure and the communities it serves to support reliable and resilient utility services, economic growth and quality of life. To learn more, visit https://www.middlesexwater.com. Please follow us on Facebook, Twitter and LinkedIn.

Media Contact:

Bernadette Sohler, Vice President – Corporate Affairs
(732) 638-7549
[email protected]



Posted on

SoCalGas and LADWP Partner to Deliver 150,000 Energy and Water Efficiency Kits to Help the Environment and Save Customers Money and Energy

Energy efficiency programs serve as one of the most cost-effective and sustainable methods to help California reach its climate goals

PR Newswire

LOS ANGELES, Dec. 22, 2020 /PRNewswire/ — The Southern California Gas Co. (SoCalGas) and the Los Angeles Department of Water and Power (LADWP) have partnered to distribute over 150,000 free energy and water efficiency kits to residents throughout Los Angeles. Each efficiency kit is equipped with simple household devices to help conserve water and natural gas and save money on utility bills. Installing these devices can reduce natural gas usage in Los Angeles by approximately 3.5 million therms and save 46,000 gallons of water per year as a result of this program.

Each kit contains a water-efficient showerhead; two bathroom faucet aerators; and a kitchen faucet aerator. The energy and water efficiency kits will be delivered SoCalGas customers in Los Angeles who have not participated in the program in the last three years throughout the month of December. Customers will also receive information on energy-saving water heaters, smart thermostats, and other appliances that are eligible for SoCalGas rebates. 

“SoCalGas and LADWP continue to help lower our environmental impact and protect our natural resources through the distribution of energy and water efficiency kits,” said Los Angeles Councilmember Joe Buscaino. “These devices are simple and easy to install and have proven to be highly impactful as we make sustainable efforts to promote saving energy and water.”

“Energy efficiency is one of the most cost-effective methods to reduce emissions,” said Brian Prusnek, director of customer programs and assistance at SoCalGas. “Not only do these programs help the environment, they’re actively helping our customers save money on their utility bills while also making a significant environmental impact as well.”

“These simple yet effective kits will help LA residents conserve water while at the same time, save on their utility bills,” said Richard Harasick, LADWP Senior Assistant General Manager of the Water System. “LADWP is proud of its long-standing partnership with SoCalGas to provide efficient, cost-saving solutions to customers’ water and energy needs, especially during these difficult times.

In the City of Los Angeles, water conservation is among the city’s multiple strategies to secure a sustainable water supply for Los Angeles and improve overall water supply reliability. With the help of LADWP’s water conservation rebates and programs, water conservation has become a way of life in Los Angeles. Water use in Los Angeles has steadily declined over the past decades, and recently reached 105 gallons of water per person per day, one of the lowest of any major U.S. city. Read more at www.ladwp.com/waterconservation.

SoCalGas is a leader in researching and developing new technologies that improve energy efficiency, reduce emissions, and keep bills affordable for customers. The utility offers rebate incentive tools and energy savings programs to help customers conserve energy and save money while promoting an environmentally sustainable future. In the past five years, SoCalGas energy efficiency programs have delivered more than 195 million therms in energy savings, enough to power over 390,000 households a year, and reducing greenhouse gas (GHG) by more than 1,000,000 metric tons, the equivalent of removing over 223,000 cars from the road. Overall, these projects have also helped SoCalGas customers save more than $217 million in utility bill costs over the past five years.

Additionally, the utility is also working to increase the production and use of renewable natural gas, which turns waste from dairies, farms, wastewater and landfills, into a source of clean and renewable energy to fuel homes and businesses. The utility recently began field testing a new technology that can simultaneously separate and compress hydrogen from a blend of hydrogen and natural gas to be transported through the natural gas pipeline system to help make a significant contribution towards a cleaner energy future. Learn more on ways to become more energy efficient through our various programs and incentives here.

About SoCalGas

Headquartered in Los Angeles, SoCalGas® is the largest gas distribution utility in the United States. SoCalGas delivers affordable, reliable, clean and increasingly renewable gas service to 21.8 million customers across 24,000 square miles of Central and Southern California, where more than 90 percent of residents use natural gas for heating, hot water, cooking, drying clothes or other uses. Gas delivered through the company’s pipelines also plays a key role in providing electricity to Californians— about 45 percent of electric power generated in the state comes from gas-fired power plants.

SoCalGas’ vision is to be the cleanest gas utility in North America, delivering affordable and increasingly renewable energy to its customers. In support of that vision, SoCalGas is committed to replacing 20 percent of its traditional natural gas supply with renewable natural gas (RNG) by 2030. Renewable natural gas is made from waste created by dairy farms, landfills and wastewater treatment plants. SoCalGas is also committed to investing in its gas delivery infrastructure while keeping bills affordable for our customers. From 2014 through 2018, the company invested nearly $6.5 billion to upgrade and modernize its pipeline system to enhance safety and reliability. SoCalGas is a subsidiary of Sempra Energy (NYSE: SRE), an energy services holding company based in San Diego. For more information visit socalgas.com/newsroom or connect with SoCalGas on Twitter (@SoCalGas), Instagram (@SoCalGas) and Facebook.  

About LADWP

The Los Angeles Department of Water and Power is the nation’s largest municipal utility, with an 8,000 megawatt (MW) electric capacity and serving an average of 436 million gallons of water per day to the more than 4 million residents of the City of Los Angeles, its businesses and visitors. For more than 100 years, LADWP has provided the city with reliable water and power service in a cost effective and environmentally responsible manner.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/socalgas-and-ladwp-partner-to-deliver-150-000-energy-and-water-efficiency-kits-to-help-the-environment-and-save-customers-money-and-energy-301197710.html

SOURCE Southern California Gas Company

Posted on

Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants

Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants

AUSTIN, Texas–(BUSINESS WIRE)–
Genprex, Inc. (Nasdaq: GNPX) (“Genprex” or the “Company”), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor for the purchase and sale of 3,116,884 shares of its common stock at a purchase price of $3.85 per share in a registered direct offering priced at-the-market under Nasdaq rules. No warrants will be issued in connection with the transaction. The closing of the offering is expected to occur on or about December 24, 2020, subject to the satisfaction of customary closing conditions.

A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-239134) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected]. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and Private Securities Litigation Reform Act, as amended, including those relating to the timing and completion of the proposed offering and other statement that are predictive in nature. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any results, performance or achievements expressed or implied by the forward-looking statements. Such factors include the risk factors set forth in the Company’s filings with the SEC, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K filed in 2020, as well as the risks identified in the shelf registration statement and the prospectus supplement relating to the offering. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. Genprex undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Genprex, Inc.

(877) 774-GNPX (4679)

Investor Relations

GNPX Investor Relations

(877) 774-GNPX (4679) ext. #2

[email protected]

Media Contact

Genprex Media Relations

Kalyn Dabbs

(877) 774-GNPX (4679) ext. #3

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Biotechnology Diabetes Health Genetics Clinical Trials

MEDIA:

Logo
Logo
Posted on

LEADING ROSEN LAW FIRM Reminds Covia Holdings Corporation f/k/a Fairmount Santrol Holdings Inc. Investors of Important February 8 Deadline in Securities Class Action First Filed by the Firm; Encourages Investors with Losses in Excess of $100K to Contact the Firm – CVIAQ, CVIA, FMSA

NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Covia Holdings Corporation f/k/a Fairmount Santrol Holdings Inc. (“Covia”) (OTC: CVIAQ) (NYSE: CVIA) (NYSE: FMSA) between March 15, 2016 to June 29, 2020, inclusive (the “Class Period”), of the important February 8, 2021 lead plaintiff deadline in the first filed securities class action commenced by the firm. The lawsuit seeks to recover damages for Covia investors under the federal securities laws.

To join the Covia class action, go to http://www.rosenlegal.com/cases-register-1993.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Covia’s proprietary “value-added” proppants were not necessarily more effective than ordinary sand; (2) Covia’s revenues, which were dependent on its proprietary “value-added” proppants, was based on misrepresentations; (3) when Covia insiders raised this issue, defendants did not take meaningful steps to rectify the issue; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 8, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1993.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com



Posted on

Arcadia Biosciences (RKDA) Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

— Net proceeds to fuel GoodWheat™ direct-to-consumer, e-commerce and retail customer acquisition and revenue generation —

PR Newswire

DAVIS, Calif., Dec. 22, 2020 /PRNewswire/ — Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, today announced the closing of its previously announced registered direct offering of 2,618,658 shares of its common stock. The offering was priced at-the-market at a purchase price per share of $2.93, for gross proceeds of approximately $7.7 million. Additionally, in a concurrent private placement, Arcadia issued unregistered warrants to purchase up to 2,618,658 shares of common stock, representing 100 percent of the shares of common stock purchased in the registered direct offering. Each warrant was sold at a price of $0.125 per underlying warrant share for gross proceeds of approximately $327,000. Each warrant has an exercise price of $3.00 per share, is exercisable immediately and will expire five and one-half years from the issuance date.

The net proceeds of the offering are estimated to be approximately $7.3 million after deducting placement agent fees and other estimated offering expenses. Arcadia intends to use the net proceeds from this offering to fund GoodWheat customer acquisition costs, including digital marketing programs, brand and retail channel development and general corporate costs.

“Firmly establishing our GoodWheat family of consumer brands, including Three Farm Daughters, and ensuring our digital marketing assets are properly built for scale is essential to the successful ramp up of our revenues in 2021,” said Matthew Plavan, president and CEO of Arcadia. “We believe the proceeds of this financing provide the capital to properly fund these efforts and better equip us to stay the course even amidst potential continued economic volatility in 2021.”

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The shares of common stock described above (but not the warrants or the shares of common stock underlying the warrants) were offered pursuant to a “shelf” registration statement (File 333-224893) filed with the Securities and Exchange Commission (SEC) and declared effective on June 8, 2018. The offering of such shares of common stock was made by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained on the SEC’s website at www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by emailing [email protected] or by calling (646) 975-6996.

The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Arcadia Biosciences, Inc.
Arcadia Biosciences (Nasdaq: RKDA) is a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients. The company’s GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. Arcadia’s GoodHempTM seed catalog delivers genetically superior hemp seeds, transplants and extracts, applying the company’s proprietary crop innovation technology, ArcaTech™, to an emerging crop. For more information, visit www.arcadiabio.com.

Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s expectations regarding the intended use of proceeds from the offering and the impact of these proceeds on the company’s business. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, without limitation, the future capital requirements of the company are different than expected and other risks set forth in the company’s filings with the Securities and Exchange Commission from time to time, including the risks set forth in the company’s annual report on Form 10-K for the year ended December 31, 2019 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.

LinkedIn: Arcadia Biosciences
Twitter: @ArcadiaAg

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/arcadia-biosciences-rkda-announces-closing-of-8-0-million-registered-direct-offering-priced-at-the-market-301197689.html

SOURCE Arcadia Biosciences, Inc.

Posted on

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still’s Disease

ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) — Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that its Investigational New Drug Application (IND) to study the use of CERC-007 to treat Still’s disease has been accepted by the United States Food and Drug Administration (FDA) and is now open. CERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb). The first study will be a global multicenter Phase 1b clinical trial in adult onset Still’s disease and is planned to start in the first quarter of 2021. Initial data is expected in the second quarter of 2021.

“Adult onset Still’s disease (AOSD) is a rare inflammatory disease resulting in joint damage, high fever and rashes,” said H. Jeffrey Wilkins, MD, Chief Medical Officer of Cerecor. “The hallmark of AOSD is elevated IL-18 levels. Targeting IL-18 using CERC-007 is a novel therapeutic approach for the treatment of AOSD.”

The planned Phase 1b clinical trial will be a global multi-center, open-label trial of CERC-007 that will enroll approximately 12 subjects with active AOSD. The primary objectives of the study will be to determine the safety and tolerability of CERC-007, and assess preliminary efficacy as measured by reductions in systemic clinical manifestations and markers of inflammation in subjects with AOSD.

About Still’s disease

Still’s disease is a serious and rare auto-inflammatory disorder that affects the entire body. There are two major forms of the disease: adult onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA). AOSD and sJIA share common clinical manifestations, including episodes of high, spiking fevers, rash, joint pain, muscle pain, sore throat, multiorgan involvement and elevated levels of IL-18.

About CERC-007

CERC-007 is a high affinity, fully human monoclonal antibody targeting the proinflammatory cytokine IL-18. It is in development for multiple auto-immune diseases, including Still’s disease (adult onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM).

About Cerecor

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases.  The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases.  The company’s rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007.  CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn’s disease, and COVID-19 acute respiratory distress syndrome.  CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still’s disease (adult onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.

For more information about Cerecor, please visit www.cerecor.com. 

Forward-Looking Statements

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Cerecor’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Cerecor’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: the development of product candidates or products; timing and success of trial results and regulatory review; potential attributes and benefits of product candidates; and other statements that are not historical. These statements are based upon the current beliefs and expectations of Cerecor’s management but are subject to significant risks and uncertainties, including: drug development costs, timing and other risks, including reliance on investigators and enrollment of patients in clinical trials, which might be slowed by the COVID-19 pandemic; regulatory risks; Cerecor’s cash position and the potential need for it to raise additional capital; general economic and market risks and uncertainties, including those caused by the COVID-19 pandemic; and those other risks detailed in Cerecor’s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Cerecor expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Cerecor’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For media and investor inquiries

James Harrell
Investor Relations
Chief Commercial Officer
Cerecor Inc.
[email protected]
623.439.2220 office

 



Posted on

Eos Energy Secures Contract to provide Safe, Sustainable Storage to California Hospital

EDISON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos”), a leading manufacturer of safe, scalable, efficient, and sustainable zinc-based energy storage systems, today announced it has a firm order from Charge Bliss, Inc. (“CBI”), a renewable energy microgrid developer/builder, to provide a critical care hospital with 2 MW of energy storage using its Znyth® battery. The deal is valued at $2 million.

“We are proud to collaborate with Charge Bliss to provide safe and reliable storage for a hospital micro grid application,” said Dr. Balki Iyer, Chief Commercial Officer of Eos. “Our Znyth® battery technology is optimized for long duration storage, which is experiencing tremendous growth and rapid adoption. We hope this installation can serve as a model for other facilities with similar energy needs.”

Eos will provide this groundbreaking project with up to 2 MW of continuous power delivery upon installation, which is scheduled to take place in the second quarter of 2021. The project agreement comes after Eos recently announced that it increased its projected pipeline by 30 percent in a 30-day period, as a result of increased demand for long duration storage (>4 hours of discharge).

“Our microgrid systems are engineered to supply clean energy while reducing peak demand,” said Jon Harding, Chief Operating Officer of CBI. “Together with Eos we believe we can mitigate the risk of a power supply disruption at a facility that is absolutely critical to the community it serves. Eos is an exceptional partner and has helped us craft a cost-effective, technically superior solution for this exciting project.”

CBI is engineering the first microgrid to be interconnected with the essential power supply of a California hospital, which is designed to support continuous facility operations including during grid outages. This project is funded, in part, through a more than $8 million grant from the California Energy Commission.

About Eos

Eos Energy Enterprises, Inc. is accelerating the shift to clean energy with positively ingenious solutions that transform how the world stores power. Our breakthrough Znyth® aqueous zinc battery was designed to overcome the limitations of conventional lithium-ion technology. Safe, scalable, efficient, sustainable — and manufactured in the U.S. — it’s the core of our innovative systems that today provide utility, industrial, and commercial customers with a proven, reliable energy storage alternative. Eos was founded in 2008 and is headquartered in Edison, New Jersey. For more information about Eos (NASDAQ: EOSE), visit eose.com.

About Charge Bliss

Charge Bliss was organized in 2011 to combine intelligent technologies for building energy management with electric vehicle charging. By integrating optimal renewable energy components and energy storage systems, Charge Bliss strives to simultaneously lower the business and facilities’ energy costs significantly while providing ancillary benefits such as clean, efficient, and resilient power. Working with diverse stakeholders including utilities, business owners, interest groups, and industry leaders, Charge Bliss has developed a unique and comprehensive approach to renewable energy microgrids that is scalable for nearly all sizes of business.

Forward-Looking Statements

This press release includes certain statements that may constitute “forward-looking statements” for purposes of the federal securities laws. Forward-looking statements include, but are not limited to, statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about: the future financial performance of Eos; Eos’s plans for expansion and acquisitions; and changes in Eos’s strategy, future operations, financial position, estimated revenues, and losses, projected costs, prospects, plans and objectives of management. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing the parties’ views as of any subsequent date, and Eos does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You should not place undue reliance on these forward-looking statements. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against Eos; (2) the ability to maintain the listing of Eos’s shares of common stock on NASDAQ; (3) the ability of Eos’s business to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (4) changes in applicable laws or regulations; (5) the possibility that Eos may be adversely affected by other economic, business, and/or competitive factors; and (6) other risks and uncertainties indicated from time to time in the Prospectus included as part of the Registration Statement on Form S-1 filed by Eos with the Securities and Exchange Commission (“SEC”) on December 10, 2020, Registration No.333-251243, including those under the heading “Risk Factors” therein, and other factors identified in Eos’s prior and future SEC filings with the SEC, available at www.sec.gov.

Contacts Investors: Ed Yuen, [email protected]
  Media: James McCusker, [email protected]



Posted on

Northrop Grumman Announces Webcast, Conference Call of Fourth Quarter and 2020 Financial Results

FALLS CHURCH, Va., Dec. 22, 2020 (GLOBE NEWSWIRE) — Northrop Grumman Corporation (NYSE: NOC) announced today that its fourth quarter and 2020 financial results will be posted on its investor relations website on Jan. 28, 2021. Prior to the market opening, and after the filing of the earnings release on Form 8-K with the Securities and Exchange Commission, the company will issue an advisory release notifying the public of the availability of the complete and full text earnings release on the company’s website at http://investor.northropgrumman.com.

The company’s fourth quarter and 2020 conference call will be held at 9:00 a.m. Eastern time, Thursday, Jan. 28, 2021. Kathy Warden, chairman, chief executive officer and president, and Dave Keffer, chief financial officer, will review fourth quarter and 2020 results and provide 2021 guidance. The conference call will be webcast live on Northrop Grumman’s website at http://investor.northropgrumman.com. Replays of the call will be available on the Northrop Grumman website for a limited time. Presentations may be supplemented by a series of slides appearing on the company’s investor relations home page.  

Northrop Grumman solves the toughest problems in space, aeronautics, defense and cyberspace to meet the ever evolving needs of our customers worldwide. Our 90,000 employees define possible every day using science, technology and engineering to create and deliver advanced systems, products and services.

Note: Statements in this press release, and statements to be made on the conference call, including in any accompanying materials, contain or may contain statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “will,” “expect,” “anticipate,” “intend,” “may,” “could,” “should,” “plan,” “project,” “forecast,” “believe,” “estimate,” “guidance,” “outlook,” “trends,” “goals” and similar expressions generally identify these forward-looking statements. These forward-looking statements speak only as of the date when made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements after the date of this release or the date of the call, except as required by applicable law. Forward-looking statements are not guarantees of future performance and inherently involve a wide range of risks and uncertainties that are difficult to predict. A discussion of these risks and uncertainties is contained in the Company’s filings with the Securities and Exchange Commission.

Contact: Tim Paynter (Media)
  703-280-2720 (office)
  [email protected]
   
  Todd Ernst (Investors)
  703-280-4535 (office)
  [email protected]



Posted on

HMS HOLDINGS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of HMSY and Encourages Investors to Contact the Firm

NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of HMS Holdings Corp. (NASDAQ: HMSY) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Gainwell Technologies.

Click here to learn more and participate in the action.

On December 21, 2020, HMS announced that it had signed an agreement to be acquired by Gainwell for approximately $3.4 billion. Pursuant to the merger agreement, HMS stockholders will receive $37 in cash for each share of HMS common stock owned.   The deal is scheduled to close in the first half of 2021.

Bragar Eagel & Squire is concerned that HMS’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for HMS’s stockholders.

If you own shares of HMS and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at [email protected] or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Melissa Fortunato, Esq.
Alexandra Raymond, Esq.
[email protected]
www.bespc.com